Closed-Loop Artificial Pancreas Using Subcutaneous Glucose Sensing and Insulin Delivery and a Model Predictive Control Algorithm: The Virginia Experience
Искусственная поджелудочная железа с замкнутым контуром на основе подкожного мониторинга глюкозы и введения инсулина и алгоритма управления с прогнозированием по модели: опыт Вирджинии
2009-09-01
SCID: 54.1/d2bg2n3m
Discuss with AI
artificial pancreasclosed-loop insulin deliverycontinuous glucose monitoringmodel predictive controltype 1 diabetes
Figures from the paper
Abstract (AI)
BACKGROUND: Recent progress in the development of clinically accurate continuous glucose monitors (CGMs), automated continuous insulin infusion pumps, and control algorithms for calculating insulin doses from CGM data have enabled the development of prototypes of subcutaneous closed-loop systems for controlling blood glucose (BG) levels in type 1 diabetes. The use of a new personalized model predictive control (MPC) algorithm to determine insulin doses to achieve and maintain BG levels between 70 and 140 mg/dl overnight and to control postprandial BG levels is presented. METHODS: Eight adults with type 1 diabetes were studied twice, once using their personal open-loop systems to control BG overnight and for 4 h following a standardized meal and once using a closed-loop system that utilizes the MPC algorithm to control BG overnight and for 4 h following a standardized meal. Average BG levels, percentage of time within BG target of 70-140 mg/dl, number of hypoglycemia episodes, and postprandial BG excursions during both study periods were compared. RESULTS: With closed-loop control, once BG levels achieved the target range (70-140 mg/dl), they remained within that range throughout the night in seven of the eight subjects. One subject developed a BG level of 65 mg/dl, which was signaled by the CGM trend analysis, and the MPC algorithm directed the discontinuance of the insulin infusion. The number of overnight hypoglycemic events was significantly reduced (p = .011) with closed-loop control. Postprandial BG excursions were similar during closed-loop and open-loop control. CONCLUSION: Model predictive closed-loop control of BG levels can be achieved overnight and following a standardized breakfast meal. This "artificial pancreas" controls BG levels as effectively as patient-directed open-loop control following a morning meal but is significantly superior to open-loop control in preventing overnight hypoglycemia.
Key Findings
1
A personalized model predictive control algorithm enabled subcutaneous closed-loop insulin delivery targeting overnight glucose levels of 70–140 mg/dl.
2
After reaching the target range, glucose remained within 70–140 mg/dl overnight in seven of eight adults with type 1 diabetes.
3
Closed-loop control significantly reduced overnight hypoglycemic events compared with patient-directed open-loop control (p = .011).
4
Postprandial glucose excursions after a standardized breakfast were similar with closed-loop and open-loop control, indicating comparable meal-time effectiveness.
5
The system detected a glucose decline to 65 mg/dl and automatically discontinued insulin infusion in one subject.
Research Object
Subcutaneous closed-loop artificial pancreas systems in adults with type 1 diabetes
Research Subject
Model predictive closed-loop control of overnight and postprandial blood glucose, including target-range maintenance and hypoglycemia prevention
Publication Details
Publication Date
2009-09-01
Journal
Journal of Diabetes Science and Technology
Publisher
SAGE Publishing
ISSN
1932-2968
Cited by
199
Open access PDF
Access Type
Author Information
Download PDF
Subscribe to digest
References available in scid.ai4
Cited by4
Zone Model Predictive Control: A Strategy to Minimize Hyper- and Hypoglycemic Events2010
The Artificial Pancreas: Is it Important to Understand How the β Cell Controls Blood Glucose?2013
Reducing risk of closed loop control of blood glucose in artificial pancreas using fractional calculus2014
In Silico Evaluation of an Artificial Pancreas Combining Exogenous Ultrafast-Acting Technosphere Insulin with Zone Model Predictive Control2013